K-type cross-shaped two-way connector for sclerotherapy of esophageal and gastric fundus varicose veins

Abstract

The utility model discloses a K type cross two-way interface for hardening treatment of esophageal and gastric fundus varicose veins, which relates to the technical field of pipe connecting components and comprises a first through pipe, a conversion cavity is arranged at one end of the first through pipe, a fourth through pipe is arranged at the other end of the conversion cavity, a second through pipe is arranged on one side of the conversion cavity, and a third through pipe is arranged on the other side of the second through pipe. A conversion plate is arranged in the conversion cavity and composed of a first gate plate, a second gate plate, a third gate plate and a fourth gate plate, the first gate plate and the fourth gate plate are oppositely arranged, the included angle between the second gate plate and the third gate plate is 90 degrees, and the included angle between the second gate plate and the fourth gate plate is 45 degrees. The included angle between the first gate plate and the second gate plate is 45 degrees. By arranging a series of structures, the lauromacrogol injection, the tissue glue injection and the 50% glucose injection can be respectively injected without pulling and inserting the liquid injection tube, so that the liquid medicine injection efficiency is improved, and the leakage risk is reduced.

Description

TECHNICAL FIELD

[0001] The utility model relates to pipe joint component technical field, concretely is a K type cross two -way interface for esophageal gastric fundus varicosity sclerotherapy. BACKGROUND

[0002] Esophageal gastric fundus varicosity sclerotherapy is a treatment method for esophageal gastric fundus varicosity, and esophageal gastric fundus varicosity is usually a complication caused by portal hypertension in decompensated cirrhosis, when varicosity reaches a certain degree, serious conditions such as digestive tract hemorrhage can occur, and sclerotherapy can be used for hemostasis and prevention of rebleeding and other purposes, and during esophageal gastric fundus varicosity sclerotherapy, polyglycol injection, tissue glue injection and 50% glucose injection are alternately injected for treatment.

[0003] When different liquid medicines are injected, the currently used method is mostly to inject different liquid medicines by continuously replacing infusion tubes, and when injection is carried out, liquid medicine leakage and waste can easily occur, and frequent replacement of infusion tubes can easily cause the interface to break, affecting the injection efficiency. UTILITY MODEL CONTENT

[0004] The utility model aims at providing a K type cross two -way interface for esophageal gastric fundus varicosity sclerotherapy to solve the problems in the above background.

[0005] In order to achieve the above object, the utility model provides the following technical scheme: A K type cross two -way interface for esophageal and gastric fundus varicose sclerotherapy, including first pipe, one end of first pipe is provided with conversion cavity, the other end of conversion cavity is provided with fourth pipe, one side of conversion cavity is provided with second pipe, the inside of conversion cavity is provided with conversion plate, the conversion plate is by clockwise direction and is composed of first gate plate, second gate plate, third gate plate and fourth gate plate in proper order, first gate plate and fourth gate plate are opposite and set up, the included angle between second gate plate and third gate plate is 90 DEG, the included angle between second gate plate and fourth gate plate is 45 DEG, the included angle between first gate plate and second gate plate is 45 DEG, the top end middle position of conversion plate is provided with pivot, the outer surface of pivot is provided with limit component, limit component is by clockwise direction and is composed of first clamping plate, second clamping plate, third clamping plate, fourth clamping plate, fifth clamping plate and sixth clamping plate in proper order, first clamping plate board is located above first gate plate, second clamping plate is located above second gate plate, fifth clamping plate is located above third gate plate, sixth clamping plate is located above fourth gate plate, the included angle between third clamping plate and fourth clamping plate is 45 DEG, third clamping plate and fourth clamping plate are located above the middle position of the included angle between second gate plate and third gate plate, the top of first clamping plate extends upwards, the bottom of second clamping plate extends downwards, the top of fourth clamping plate extends upwards, the bottom of fifth clamping plate extends downwards, the top and bottom of limit component are provided with reset spring, and one end of two reset springs is fixedly connected on the outer surface of pivot, one side of limit component is provided with limit block.

[0006] Preferably, the outer surface of the pivot above the reset spring of the limit component is provided with an indicator disc, the bottom end of the indicator disc is provided with three indicator blocks matched with the first gate plate, the second gate plate and the third gate plate, the top end of the indicator block matched with the first gate plate is printed with "1-4 communication, pull up rotation", the top end of the indicator block matched with the first gate plate is printed with "2-4 communication, press down rotation", and the top end of the indicator block matched with the third gate plate is printed with "3-4 communication, pull up rotation".

[0007] Preferably, the top end of the conversion cavity is provided with an upper shell, the top of the upper shell is provided with an indicator opening matched with the indicator disc, when the indicator disc rotates with the conversion plate, the indicator disc will also rotate, and the operation indication displayed on the top end of the corresponding indicator block of the indicator opening can be observed.

[0008] Preferably, the other side of the conversion cavity is provided with a third pipe, the first pipe, the second pipe, the third pipe and the fourth pipe are equidistantly arranged on the circumferential surface of the conversion cavity in a cross shape, the fourth pipe is used for discharging the liquid medicine in the conversion cavity, the first pipe, the second pipe and the third pipe are used for injecting polyethylene glycol injection, tissue glue injection and 50% glucose injection respectively.

[0009] Preferably, the top of the conversion cavity is provided with a closing cover, which seals the top of the conversion cavity and guarantees the sealing of the conversion cavity.

[0010] Preferably, one end of the limiting block is provided with a fixing frame, which is an L-shaped component, the bottom end of the fixing frame is fixedly installed at the top end of the conversion cavity, and the front end of the fixing frame is an inclined block, and the outer surface of the inclined block is 45° and matched with the limiting assembly.

[0011] Compared with the prior art, the utility model has the advantages that:

[0012] The K-shaped cross two-way joint for esophagus and gastric fundus varicosity sclerotherapy of the utility model, through the first through pipe, the second through pipe, the third through pipe and the fourth through pipe which are circumferentially arranged on the conversion cavity, liquid medicine injection is carried out, the conversion cavity is internally provided with a conversion plate, the conversion plate is composed of a first gate plate, a second gate plate, a third gate plate and a fourth gate plate, the first gate plate, the second gate plate, the third gate plate and the fourth gate plate are K-shaped, through the rotation of the conversion plate, the first gate plate, the second gate plate, the third gate plate and the fourth gate plate are respectively communicated or blocked with the first through pipe, the second through pipe, the third through pipe and the fourth through pipe to change the communication state of the first through pipe, the second through pipe and the third through pipe and the fourth through pipe, without pulling and inserting the liquid injection pipe, laurolin injection solution, tissue glue injection solution and 50% glucose injection solution can be respectively injected, the liquid medicine injection efficiency is improved, and the leakage risk is reduced. BRIEF DESCRIPTION OF DRAWINGS

[0013] Figure 1 It is the overall structure schematic view of the utility model;

[0014] Figure 2 It is the structure schematic view of the upper shell after being disassembled of the utility model;

[0015] Figure 3 It is the internal structure schematic view of the conversion cavity of the utility model;

[0016] Figure 4 It is the structure schematic view of the utility model Figure 3 It is the enlarged structure schematic view of the structure at A of the utility model;

[0017] Figure 5 It is the structure schematic view of the rotating shaft of the utility model;

[0018] Figure 6 It is the structure schematic view of the limiting assembly of the utility model;

[0019] Figure 7 It is the structure schematic view of the conversion cavity of the utility model;

[0020] Figure 8 It is the structure schematic view of the conversion plate of the utility model.

[0021] Fig. 1, first pipe; 2, second pipe; 3, third pipe; 4, fourth pipe; 5, conversion cavity; 6, indicating opening; 7, rotating shaft; 8, upper shell; 9, closing cover; 10, reset spring; 11, indicating disc; 12, limiting block; 13, limiting assembly; 1301, first clamping plate; 1302, second clamping plate; 1303, third clamping plate; 1304, fourth clamping plate; 1305, fifth clamping plate; 1306, sixth clamping plate; 14, conversion plate; 1401, first gate plate; 1402, second gate plate; 1403, third gate plate; 1404, fourth gate plate; 15, fixing frame. DETAILED DESCRIPTION

[0022] The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of protection of the present application.

[0023] In the description of the present application, it should be noted that the terms "upper", "lower", "inner", "outer", "front end", "rear end", "two ends", "one end", "the other end" and the like indicate the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the present application and simplifying the description, and do not indicate or imply that the devices or elements referred to must have a particular orientation, be constructed and operated in a particular orientation, and therefore cannot be understood as limiting the present application. In addition, the terms "first" and "second" are only for the purpose of description, and cannot be understood as indicating or implying relative importance.

[0024] As Figures 1 to 8As shown, the K-shaped cross two-way interface for esophageal and gastric varices sclerosis treatment of the embodiment comprises a first tube 1, one end of the first tube 1 is provided with a conversion cavity 5, the other end of the conversion cavity 5 is provided with a fourth tube 4, one side of the conversion cavity 5 is provided with a second tube 2, the other side of the conversion cavity 5 is provided with a third tube 3, the fourth tube 4 is used for discharging the liquid medicine inside the conversion cavity 5, the first tube 1, the second tube 2 and the third tube 3 are used for injecting laurolin injection, tissue glue injection and 50% glucose injection respectively, the conversion cavity 5 is internally provided with a conversion plate 14, the conversion plate 14 sequentially comprises a first gate plate 1401, a second gate plate 1402, a third gate plate 1403 and a fourth gate plate 1404 in the clockwise direction, the conversion plate 14 can rotate inside the conversion cavity 5, when the first gate plate 1401 and the fourth gate plate 1404 rotate towards the first tube 1 and the second tube 2 respectively, the third tube 3 is sealed, at this time the first tube 1 can inject laurolin injection through the fourth tube 4, when the third gate plate 1403 and the fourth gate plate 1404 are towards the third tube 3 and the fourth tube 4 respectively, the third tube 3 can inject 50% glucose injection through the fourth tube 4, when the third gate plate 1403 and the fourth gate plate 1404 are towards the second tube 2 and the fourth tube 4 respectively, the second tube 2 can inject tissue glue injection through the fourth tube 4, the first gate plate 1401 and the fourth gate plate 1404 are oppositely arranged, the included angle between the second gate plate 1402 and the third gate plate 1403 is 90°, the included angle between the second gate plate 1402 and the fourth gate plate 1404 is 45°, the included angle between the first gate plate 1401 and the second gate plate 1402 is 45°, the top end of the conversion plate 14 is provided with a rotating shaft 7, the outer surface of the rotating shaft 7 is provided with a limiting component 13, the limiting component 13 sequentially comprises a first clamping plate 1301, a second clamping plate 1302, a third clamping plate 1303, a fourth clamping plate 1304, a fifth clamping plate 1305 and a sixth clamping plate 1306 in the clockwise direction, the first clamping plate 1301 is located above the first gate plate 1401, the second clamping plate 1302 is located above the second gate plate 1402, the fifth clamping plate 1305 is located above the third gate plate 1403, the sixth clamping plate 1306 is located above the fourth gate plate 1404, the included angle between the third clamping plate 1303 and the fourth clamping plate 1304 is 45°, the third clamping plate 1303 and the fourth clamping plate 1304 are located above the middle position of the included angle between the second gate plate 1402 and the third gate plate 1403, the top of the first clamping plate 1301 extends upwards, the bottom of the second clamping plate 1302 extends downwards, the top of the fourth clamping plate 1304 extends upwards, the bottom of the fifth clamping plate 1305 extends downwards, the top and the bottom of the limiting component 13 are provided with a reset spring 10, one end of the two reset springs 10 is fixedly connected to the outer surface of the rotating shaft 7, one side of the limiting component 13 is provided with a limiting block 12, the limiting block 12 limits the limiting component 13, when the limiting block 12 is located between the first clamping plate 1301 and the second clamping plate 1302,When the first shutter 1401 and the fourth shutter 1404 need to be adjusted to the communication state, the rotating shaft 7 is pulled up to make the limiting component 13 descend, then the rotating shaft 7 is rotated until the limiting block 12 is blocked by the upward extending end of the fourth clamping plate 1304, then the rotating shaft 7 is loosened, at this time, the third shutter 1403 and the fourth shutter 1404 are respectively directed to the second pipe 2 and the fourth pipe 4, and the second pipe 2 and the fourth pipe 4 are in the communication state, when the communication state is adjusted again, the rotating shaft 7 is pressed down and rotated until the limiting block 12 is blocked by the bottom extending end of the fifth clamping plate 1305, then the rotating shaft 7 is loosened, and the limiting block 12 is located between the fourth clamping plate 1304 and the fifth clamping plate 1305, at this time, the third shutter 1403 and the fourth shutter 1404 are respectively directed to the third pipe 3 and the fourth pipe 4, and the third pipe 3 and the fourth pipe 4 are in the communication state.

[0025] Specifically, the outer surface of the rotating shaft 7 above the top end reset spring 10 of the limiting component 13 is provided with an indicating disc 11, the bottom end of the indicating disc 11 is provided with three indicating blocks matched with the first shutter 1401, the second shutter 1402 and the third shutter 1403, the top end of the indicating block matched with the first shutter 1401 is printed with the words "1-4 communication, pull up and rotate", the top end of the indicating block matched with the first shutter 1401 is printed with the words "2-4 communication, press down and rotate", and the top end of the indicating block matched with the third shutter 1403 is printed with the words "3-4 communication, pull up and rotate".

[0026] Further, the top end of the conversion cavity 5 is provided with an upper shell 8, the top of the upper shell 8 is provided with an indicating opening 6 matched with the indicating disc 11, when the indicating disc 11 rotates with the conversion plate 14, the indicating disc 11 rotates at the same time, and the operation indication displayed on the top end of the corresponding indicating block can be observed through the indicating opening 6.

[0027] Further, the other side of the conversion cavity 5 is provided with a third pipe 3, the first pipe 1, the second pipe 2, the third pipe 3 and the fourth pipe 4 are equidistantly arranged on the circumferential surface of the conversion cavity 5 in a cross shape, the fourth pipe 4 is used for discharging the drug solution inside the conversion cavity 5, the first pipe 1, the second pipe 2 and the third pipe 3 are used for injecting polyethylene glycol injection, tissue glue injection and 50% glucose injection respectively.

[0028] Further, the top of the conversion cavity 5 is provided with a sealing cover 9, the sealing cover 9 seals the top of the conversion cavity 5 to ensure the sealing property of the conversion cavity 5.

[0029] Further, one end of the limiting block 12 is provided with a fixing frame 15, the fixing frame 15 is an L-shaped component, the bottom end of the fixing frame 15 is fixedly installed at the top end of the conversion cavity 5, the front end of the fixing frame 15 is an inclined block, the outer surface of the inclined block is 45°, and the inclined block is matched with the limiting assembly 13.

[0030] The use method of the embodiment is: connecting the fourth tube 4 and the extracorporeal infusion tube in the esophageal and gastric fundus varicose sclerotherapy process, when it is needed to inject lauromacrogol injection, the first gate plate 1401 and the fourth gate plate 1404 are respectively directed to the first tube 1 and the second tube 2, then the third tube 3 is sealed, so that the first tube 1 and the fourth tube 4 are in communication, and the lauromacrogol injection is injected into the first tube 1 and injected through the fourth tube 4, when it is needed to inject tissue glue injection, the limiting assembly 13 is lowered by pulling the rotating shaft 7, then the rotating shaft 7 is rotated until the limiting block 12 is blocked by the upward extending end of the fourth clamping plate 1304, so that the limiting block 12 is located between the fourth clamping plate 1304 and the fifth clamping plate 1305, then the rotating shaft 7 is loosened, at this time, the third gate plate 1403 and the fourth gate plate 1404 are respectively directed to the second tube 2 and the fourth tube 4, and the second tube 2 and the fourth tube 4 are in communication, and the tissue glue injection is injected into the second tube 2 and injected through the fourth tube 4, when it is needed to inject 50% glucose injection, the rotating shaft 7 is pressed and rotated until the limiting block 12 is blocked by the bottom end extending end of the fifth clamping plate 1305, then the rotating shaft 7 is loosened, so that the limiting block 12 is located between the fourth clamping plate 1304 and the fifth clamping plate 1305, at this time, the third gate plate 1403 and the fourth gate plate 1404 are respectively directed to the third tube 3 and the fourth tube 4, so that the third tube 3 and the fourth tube 4 are in communication, and the 50% glucose injection is injected into the third tube 3 and injected through the fourth tube 4.

[0031] Finally, it should be noted that the above only describes the preferred embodiments of the present application and is not intended to limit the present application, although the present application has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions recorded in the foregoing embodiments or make equivalent replacement for some technical features. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application shall be included in the protection scope of the present application.

Claims

1. A K-shaped cross two-way connector for esophageal-gastropyloric varicose sclerosis treatment, comprising a first tube (1), characterized in that: One end of the first pipe (1) is provided with a conversion cavity (5), the other end of the conversion cavity (5) is provided with a fourth pipe (4), one side of the conversion cavity (5) is provided with a second pipe (2), the other side of the conversion cavity (5) is provided with a third pipe (3), the inside of the conversion cavity (5) is provided with a conversion plate (14), the conversion plate (14) is composed of a first gate plate (1401), a second gate plate (1402), a third gate plate (1403) and a fourth gate plate (1404) in turn in clockwise direction, the first gate plate (1401) and the fourth gate plate (1404) are oppositely arranged, the included angle between the second gate plate (1402) and the third gate plate (1403) is 90°, the included angle between the second gate plate (1402) and the fourth gate plate (1404) is 45°, the included angle between the first gate plate (1401) and the second gate plate (1402) is 45°, the top end of the conversion plate (14) is provided with a rotating shaft (7) at the middle position, the outer surface of the rotating shaft (7) is provided with a limiting assembly (13), the limiting assembly (13) is composed of a first clamping plate (1301), a second clamping plate (1302), a third clamping plate (1303), a fourth clamping plate (1304), a fifth clamping plate (1305) and a sixth clamping plate (1306) in turn in clockwise direction, the first clamping plate (1301) is located above the first gate plate (1401), the second clamping plate (1302) is located above the second gate plate (1402), the fifth clamping plate (1305) is located above the third gate plate (1403), the sixth clamping plate (1306) is located above the fourth gate plate (1404), the included angle between the third clamping plate (1303) and the fourth clamping plate (1304) is 45°, the third clamping plate (1303) and the fourth clamping plate (1304) are located above the middle position of the included angle between the second gate plate (1402) and the third gate plate (1403), the top of the first clamping plate (1301) extends upwards, the bottom of the second clamping plate (1302) extends downwards, the top of the fourth clamping plate (1304) extends upwards, the bottom of the fifth clamping plate (1305) extends downwards, the top and the bottom of the limiting assembly (13) are both provided with a reset spring (10), one end of the two reset springs (10) is respectively fixedly connected to the outer surface of the rotating shaft (7), one side of the limiting assembly (13) is provided with a limiting block (12).

2. The K-type cross over port for esophagogastric varices sclerotherapy according to claim 1, characterized in that: The outer surface of the rotating shaft (7) above the reset spring (10) of the top of the limiting assembly (13) is provided with an indicating disc (11), the bottom of the indicating disc (11) is provided with three indicating blocks matched with the first gate plate (1401), the second gate plate (1402) and the third gate plate (1403).

3. The K-type cross over port for esophagogastric varices sclerotherapy according to claim 2, characterized in that: The top of the conversion cavity (5) is provided with an upper shell (8), the top of the upper shell (8) is provided with an indicating opening (6) matched with the indicating disc (11).

4. The K-type cross over port for esophagogastric varices sclerotherapy according to claim 1, characterized in that: The first through pipe (1), the second through pipe (2), the third through pipe (3) and the fourth through pipe (4) are arranged equidistantly on the circumferential surface of the conversion cavity (5) in a cross shape.

5. The K-type cross over port for esophagogastric varices sclerotherapy according to claim 1, characterized in that: The top of the conversion cavity (5) is provided with a closing cover (9).

6. The K-type cross over port for esophagogastric varices sclerotherapy according to claim 1, characterized in that: One end of the limiting block (12) is provided with a fixing frame (15), the fixing frame (15) is an L-shaped part, and the bottom end of the fixing frame (15) is fixedly installed at the top end of the conversion cavity (5).

Images